BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis

Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained...